Presumably differentiated neuroblastoma cell lines are more sensitive to RSL3 treatment (i.e., GPX4 inhibition) rather than erastin (the system xc- inhibitor) because these cells already have higher basal levels of cysteine due to the upregulation of SLC7A11 during the differentiation process. The gene discussed is SLC7A11; the disease is neuroblastoma.